EMA starts review of Cidara's candidiasis therapy rezafungin

The EU regulator has started its review of Cidara Therapeutics' once-weekly antifungal rezafungin, setting up a decision next year as a new option for serious, invasive infections caused by

Cidara and Mundipharma prep filings for antifungal rezafungi...

Mundipharma and Cidara Therapeutics have reported the results of a phase 3 trial of their new once-weekly antifungal rezafungin, setting up regulatory filings in t

New deals extend Mundipharma biosimilar reach

Mundipharma, Grünenthal accused of kickbacks in Italy

Two manufacturers of opioid analgesics – Mundipharma and Grünenthal – have been accused of paying an Italian doctor to promote use of the drugs.

Mundipharma's Neulasta biosimilar approved in EU

A second cut-price biosimilar of Amgen’s Neulasta (pegfilgrastim) long-acting white blood cell booster is to hit the EU market after the European Commission approved Mundipharma’s Pelmeg.

Mundipharma appoints former GSK exec as CFO

The Mundipharma network of independent pharma companies has appointed Arnaud Breabout as chief financial officer.